These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 25224525)

  • 1. American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome.
    Chang L; Lembo A; Sultan S
    Gastroenterology; 2014 Nov; 147(5):1149-72.e2. PubMed ID: 25224525
    [No Abstract]   [Full Text] [Related]  

  • 2. American Gastroenterological Association Institute Guideline on the pharmacological management of irritable bowel syndrome.
    Weinberg DS; Smalley W; Heidelbaugh JJ; Sultan S;
    Gastroenterology; 2014 Nov; 147(5):1146-8. PubMed ID: 25224526
    [No Abstract]   [Full Text] [Related]  

  • 3. The use of mebeverine in irritable bowel syndrome. A Position paper of the Romanian Society of Neurogastroenterology based on evidence.
    Dumitrascu DL; Chira A; Bataga S; Diculescu M; Drug V; Gheorghe C; Goldis A; Nedelcu L; Porr PJ; Sporea I;
    J Gastrointestin Liver Dis; 2014 Dec; 23(4):431-5. PubMed ID: 25532003
    [No Abstract]   [Full Text] [Related]  

  • 4. How can we achieve relief of bowel and abdominal symptoms for patients with irritable bowel syndrome with constipation?
    Tack J
    Expert Rev Gastroenterol Hepatol; 2013 Jul; 7(5 Suppl 1):21-6. PubMed ID: 23859757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lubiprostone (Amitiza) for irritable bowel syndrome with constipation.
    Med Lett Drugs Ther; 2008 Jul; 50(1290):53-4. PubMed ID: 18617872
    [No Abstract]   [Full Text] [Related]  

  • 6. End points in irritable bowel syndrome.
    Mangel AW; Fehnel SE
    Expert Rev Gastroenterol Hepatol; 2011 Jun; 5(3):293-5. PubMed ID: 21651345
    [No Abstract]   [Full Text] [Related]  

  • 7. Linaclotide for treatment of irritable bowel syndrome--the view of European regulators.
    Berntgen M; Enzmann H; Schabel E; Prieto Yerro C; Gómez-Outes A; Salmonson T; Musaus J
    Dig Liver Dis; 2013 Sep; 45(9):724-6. PubMed ID: 23701993
    [No Abstract]   [Full Text] [Related]  

  • 8. A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation.
    Johnston JM; Shiff SJ; Quigley EM
    Curr Med Res Opin; 2013 Feb; 29(2):149-60. PubMed ID: 23198977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of irritable bowel syndrome with constipation: a flexible approach to treating a complex condition with multiple symptoms.
    Layer P
    Expert Rev Gastroenterol Hepatol; 2013 Jul; 7(5 Suppl 1):9-14. PubMed ID: 23859755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linaclotide, novel therapy for the treatment of chronic idiopathic constipation and constipation-predominant irritable bowel syndrome.
    Vazquez-Roque MI; Bouras EP
    Adv Ther; 2013 Mar; 30(3):203-11. PubMed ID: 23436110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Joint Statement of the German Society for Digestive and Metabolic Diseases (DGVS), the German Society for Neurogastroenterology and motility (DGNM) and the German Society for Internal Medicine (DGIM) for linaclotide-benefit assessment of the Institute for Quality and Efficiency in Health Care (IQWiG) in accordance with § 35a SGB V (dossier evaluation)].
    Andresen V; Layer P; ; ;
    Z Gastroenterol; 2013 Oct; 51(10):1199-1201. PubMed ID: 24266047
    [No Abstract]   [Full Text] [Related]  

  • 12. Focus on Pharmacotherapy for Irritable Bowel Syndrome with Constipation.
    Liu JJ; Brenner DM
    Gastroenterol Clin North Am; 2021 Sep; 50(3):639-653. PubMed ID: 34304792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging receptor target in the pharmacotherapy of irritable bowel syndrome with constipation.
    Blackshaw LA; Brierley SM
    Expert Rev Gastroenterol Hepatol; 2013 Jul; 7(5 Suppl 1):15-9. PubMed ID: 23859756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tegaserod in treatment of women with irritable bowel syndrome].
    Munck LK; Ainsworth MA
    Ugeskr Laeger; 2007 Jun; 169(23):2190-2. PubMed ID: 17592683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease.
    Feuerstein JD; Nguyen GC; Kupfer SS; Falck-Ytter Y; Singh S;
    Gastroenterology; 2017 Sep; 153(3):827-834. PubMed ID: 28780013
    [No Abstract]   [Full Text] [Related]  

  • 16. [Treatment experience of patients with irritable bowel syndrome complicated by constipations with medicinal preparation softovak].
    Ruchkina IN; Lychkova AE; Parfenov AI
    Eksp Klin Gastroenterol; 2007; (5):103-6. PubMed ID: 18389606
    [No Abstract]   [Full Text] [Related]  

  • 17. Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies.
    Jadallah KA; Kullab SM; Sanders DS
    World J Gastroenterol; 2014 Jul; 20(27):8898-909. PubMed ID: 25083062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome.
    Khoshoo V; Armstead C; Landry L
    Aliment Pharmacol Ther; 2006 Jan; 23(1):191-6. PubMed ID: 16393297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guanylate cyclase C agonists: emerging gastrointestinal therapies and actions.
    Camilleri M
    Gastroenterology; 2015 Mar; 148(3):483-7. PubMed ID: 25576859
    [No Abstract]   [Full Text] [Related]  

  • 20. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation.
    Chang L; Sultan S; Lembo A; Verne GN; Smalley W; Heidelbaugh JJ
    Gastroenterology; 2022 Jul; 163(1):118-136. PubMed ID: 35738724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.